When seeking orphan drug approval, demonstrating value for therapies can be a challenge. The limited amount of data available affects the feasibility of developing models that meet good practice recommendations for health technology assessment submissions. We will discuss different approaches for developing a robust model structure that can help you with orphan drug reimbursement.
